271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
Showing 1 to 5 of 5 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048756 | 2021-07-19 | 2021-07-16 | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | ankylosing spondylitis | Non-exposed group: Meloxicam tablets, once a day, one tablet at a time. According to the patient's condition, sulfasalazine tablets and other recommended anti-rheumatic drugs for the treatment of AS/SpA can be added.;Exposed group:On the basis of the non-exposure group, Yunpi Yishen Jiedu Tongdu granules were added. ; Non-exposed group: Meloxicamtablets, once a day, one tablet at a time. According to the patient's co ... | Zhejiang University of Traditional Chinese Medicine | NULL | Pending | 18 | 65 | Both | Non-exposed group:125;Exposed group:125; | N/A | China |
| 2 | ITMCTR2100005056 | 2021-07-19 | 2021-07-16 | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | ankylosing spondylitis | Non-exposed group: Meloxicam tablets, once a day, one tablet at a time. According to the patient's condition, sulfasalazine tablets and other recommended anti-rheumatic drugs for the treatment of AS/SpA can be added.;Exposed group:On the basis of the non-exposure group, Yunpi Yishen Jiedu Tongdu granules were added. ; Non-exposed group: Meloxicamtablets, once a day, one tablet at a time. According to the patient's co ... | Zhejiang University of Traditional Chinese Medicine | NULL | Pending | 18 | 65 | Both | Non-exposed group:125;Exposed group:125; | N/A | China |
| 3 | NCT03473665 (ClinicalTrials.gov) | March 1, 2018 | 13/3/2018 | Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis | Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study | Ankylosing Spondylitis;Axial Spondyloarthritis | Drug: Indomethacin;Drug: Diclofenac;Drug: Meloxicam;Drug: Celecoxib | Columbia University | NULL | Terminated | 18 Years | N/A | All | 9 | Phase 4 | United States |
| 4 | NCT04480359 (ClinicalTrials.gov) | October 1, 2017 | 16/7/2020 | Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis | The Clinical Research of the Traditional Chinese Medicine Bawei Shenqi Pill in the Treatment of the Kidney Yang Deficiency Type of Ankylosing Spondylitis The Clinical Research of the Traditional Chinese Medicine Bawei Shenqi Pill in the Treatment of the ... | Ankylosing Spondylitis | Drug: Bawei Shenqi Pill;Drug: Bawei Shenqi Pill placebo;Drug: Meloxicam | Shanghai University of Traditional Chinese Medicine | NULL | Recruiting | 18 Years | 70 Years | All | 80 | Phase 2/Phase 3 | China |
| 5 | NCT02183168 (ClinicalTrials.gov) | July 2001 | 4/7/2014 | Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis Evaluation of Efficacy and Safety of MeloxicamSuppository (15mg Daily) and Tablet (15 mg Daily) Comp ... | A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of MeloxicamSuppository (15mg Dail ... | Spondylitis, Ankylosing | Drug: Meloxicam suppository;Drug: Meloxicam tablet;Drug: Indomethacin | Boehringer Ingelheim | NULL | Completed | N/A | N/A | Both | 192 | Phase 3 | NULL |